David G. Huntsman
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (43)
Kaplan–Meier curves of OS in ( A ) main tumor groups ( n = 582)—MBOT, MOC, LGI, and UGI; ( B ) patients with MOC by FIGO stage ( n = 184); ( C ) patients with MOC by pattern of invasion in all stages ( n = 178); and ( D ) patients with stage I MOC ( n = 134), by pattern of invasion.
Year:
2025
Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.
Year:
2025
Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis ( n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.
Year:
2025
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) is a rare, aggressive cancer affecting young women driven by inactivating mutations in SMARCA4 , a key SWI/SNF chromatin remodeling gene. To uncover its druggable vulnerabilities, we performed a compound screen and found that SCCOHT cells and tumors were sensitive to PARP inhibitors. Paradoxically, SCCOHT displayed BRCA-deficient traits despite retaining wild-type BRCA1 expression. Elevated R-loop in SCCOHT sequestered BRCA1, limiting its availability for DNA damage repair. Proximity-dependent biotin identification revealed that wild-type SMARCA4, but not its pathogenic variants, promoted RNA polymerase II (Pol II) elongation by mediating the assembly of the polymerase-associated factor 1 complex. Thus, SMARCA4 loss increased Pol II pausing, resulting in elevated R-loops and BRCA1 redistribution. The suppression of BRCA1 activity sensitized SMARCA4-deficient SCCOHT cells and tumors to PARP inhibitors, which was further enhanced by the addition of a CDK9 inhibitor targeting Pol II elongation. Cotargeting PARP/CDK9 also elicited synergistic effects against other undifferentiated ovarian cancer cells with SMARCA4 loss. These findings link SMARCA4 loss to perturbed Pol II elongation and compromised DNA repair by BRCA1, providing a therapeutic opportunity to target SCCOHT and other SWI/SNF-deficient ovarian cancers. Significance: Pol II stalling induced by SMARCA4 loss leads to R-loop accumulation that sequesters BRCA1 to transcription complexes, underlying the sensitivity of SMARCA4-deficient ovarian cancers to inhibitors targeting PARPs and Pol II elongation.
Year:
2025
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a rare, deadly form of ovarian cancer that uniformly harbors mutations in SMARCA4, a member of the SWI/SNF chromatin remodeling complex. SWI/SNF impacts RNA splicing, and dysregulation of splicing can generate immunogenic tumor antigens. In this study, we explored the relationship between SMARCA4 loss and RNA splicing dysregulation. SCCOHT primary tumors harbored tumor-associated outlier splicing events compared with normal tissues. Many of the tumor events were retained introns encoding novel peptides predicted to bind to MHC-I complexes. Immune cells were observed in primary SCCOHT tumors, suggesting a potentially immune-reactive tumor microenvironment. Mutations in several switch/sucrose nonfermenting (SWI/SNF) subunits were associated with higher rates of outlier retained introns across tumor types in The Cancer Genome Atlas data. Interestingly, RNA sequencing of isogenic SCCOHT cell lines demonstrated a role for SMARCA4 in intron retention (IR). Distinct protein–protein interactions between splicing factors identified in SCCOHT cell lines supported a role for SMARCA4 in splicing regulation. Furthermore, SWI/SNF localized to genes, which were differentially spliced. Mass spectrometry analyses confirmed expression of some of these novel peptides, and a subset of these are predicted to bind to MHC-I complexes. A pool of these novel peptides derived from retained introns in SCCOHT triggered proliferation and expression of TNFα and INFγ in primary human T cells. Together, these data suggest that SMARCA4 loss in SCCOHT leads to IR. Furthermore, T-cell activation by novel peptides encoded by these tumor-specific splicing events suggests IR could be a source of tumor-associated antigens in SCCOHT. Significance: SCCOHT, a rare ovarian cancer, features splicing dysregulation due to SMARCA4 loss that generates immunostimulatory peptides linked to potential immune responses and therapeutic avenues, challenging traditional views of the role of SMARCA4.
Year:
2025
Clear cell ovarian cancer (CCOC) is the second most common ovarian cancer subtype, accounting for 5%–11% of ovarian cancers in North America. Late‐stage CCOC is associated with a worse prognosis compared to other ovarian cancer histotypes, a challenge that has seen limited progress in recent decades. CCOC typically originates within the toxic microenvironment of endometriotic ovarian cysts and is characterized by its intrinsic chemoresistance, a strong hypoxic signature, and abundant expression of cystathionine gamma‐lyase (CTH). CTH is a key enzyme in the transsulfuration pathway and serves as a marker of ciliated cells derived from the Müllerian tract. CTH plays a pivotal role in de novo cysteine synthesis, which is essential for glutathione (GSH) production and redox homeostasis. Using an array of molecular tools and cancer models, including in vivo studies, we demonstrated that CTH expression was induced under various stress conditions, such as exposure to endometriotic cyst content and hypoxia. This induction enables cell survival and creates a differentiation state manifested by CCOC that potentiates tumor progression and metastasis. In addition to regulating redox homeostasis, CTH enhances hypoxia inducible factor 1‐alpha (HIF1α) expression, independently of hydrogen sulfide (H 2 S) production. Re‐expression of HIF1α in CTH KO cells fully restored metastatic capacity in in vivo models. Co‐expression of CTH and HIF1α proteins was also observed in human CCOC samples. Importantly, targeting CTH in CCOC significantly reduced its metastatic potential in in vivo models and enhanced sensitivity to chemotherapy. These findings underscore that CTH is both a defining feature of CCOC and a promising therapeutic target, not only for CCOC patients but also for those with other CTH‐expressing cancers. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Year:
2025
Supplementary Table 1. Logistic regression analysis of factors associated with accepting risk-reducing surgery (RRS) for ovarian cancer when lifetime risk is less than 4% compared to greater or equal to 4%, using complete case analysis
Year:
2025
Tumor protein p53 mutated/abnormal (p53abn) endometrial carcinomas account for over 50% of deaths but comprise only 15% of all endometrial carcinomas. Most patients show limited response to standard‐of‐care chemotherapy with or without radiotherapy, and only a minority of cases are amenable to targeted therapies like poly‐ADP ribose polymerase (PARP) inhibitors and HER2‐directed therapies. Recent immunotherapy clinical trials have demonstrated remarkable efficacy, not only in mismatch repair deficient (MMRd) tumors but also in a subset of mismatch repair‐proficient (MMRp) tumors. However, the immune microenvironment and its relationship to other therapeutic targets in MMRp endometrial carcinoma remains poorly understood. Here, we characterize the immune microenvironment of p53abn endometrial carcinoma, the most clinically aggressive subtype of MMRp endometrial carcinoma, and correlate antitumor immune signatures with other targetable alterations. We accrued 256 treatment‐naïve p53abn endometrial carcinomas and systemically profiled T‐cell, B‐cell, myeloid, and tumor‐cell populations with multiplex immunofluorescence to assess the tissue localization and functional status of immune cells. Shallow whole‐genome sequencing was performed on a subset of 126 cases. Patterns of immune infiltration were compared to survival outcomes and mutational signatures. Mixture modeling divided p53abn endometrial carcinoma into tumor‐infiltrating lymphocyte (TIL)‐rich and TIL‐poor subsets. Over 50% of tumors were TIL‐rich. TIL‐rich cases overexpressed targetable immune evasion molecules and were associated with longer overall and disease‐specific survival in multivariate analysis. This effect was particularly pronounced in advanced stage disease and in patients who did not receive adjuvant chemotherapy. TIL did not associate with homologous recombination deficient mutational signatures or HER2 amplification. Our findings demonstrate a biological rationale for immunotherapy in a substantial subset of patients with p53abn endometrial cancer and may help inform combination therapies with immune checkpoint inhibition, PARP inhibitors, and anti‐HER2 agents. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Year:
2025
With evidence that salpingectomy is effective in preventing high-grade serous carcinoma, it is time to consider offering this procedure to people at higher-than-average lifetime risk for ovarian cancer, despite not having a pathogenic genetic variant that increases the risk for ovarian cancer. This targeted approach has potential to be effective at reducing ovarian cancer incidence, and unlike opportunistic salpingectomy, it is focused on people with an increased lifetime risk of ovarian cancer. However, the acceptability of this approach within the population of potential patients remains unknown. We conducted an online survey of adults in British Columbia, Canada, who were defined as “at risk” for ovarian cancer (i.e., people born with ovaries). Participants completed a questionnaire on demographics, ovarian cancer risk and protective factors, concerns about risk-reducing salpingectomy (RSS), and the risk they considered high enough to warrant RRS. We included 211 participants. Among these participants, 42% ( n = 88) indicated that they would consider RRS at any lifetime risk or any risk above the population average. Another 20 participants chose risks between 1.5% and 4% for a cumulative 51% of the sample choosing risks below thresholds for oophorectomy. In contrast, 6% ( n = 12) indicated that they would not consider the procedure at any risk level. None of the factors collected were associated with the likelihood that a person would find RRS acceptable. Overall, our participants showed broad interest in RRS as an ovarian cancer prevention strategy. These results suggest that there would likely be uptake if RRS was offered. Significance: This study found that many participants were willing to consider RRS to prevent ovarian cancer. Further research on RRS should be undertaken to understand how this can be best used for ovarian cancer prevention.
Year:
2025
Supplementary Table 1. Logistic regression analysis of factors associated with accepting risk-reducing surgery (RRS) for ovarian cancer when lifetime risk is less than 4% compared to greater or equal to 4%, using complete case analysis
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (86)
Jessica N. McAlpine
Chew Wei Chair Gynecologic Oncology, Division Head
The University of British Columbia
Charlie Gourley
University of Edinburgh
Sue K. Park
Professor
Seoul National University College of Medicine
Elizabeth Christie
Peter MacCallum Cancer Institute
Timothy Budden
Lecturer
University of Liverpool
Beth Karlan
Vice Chair
University of California, Los Angeles
William Foulkes
Full Professor
McGill University
Anna Jakubowska
Head
Pomeranian Medical University
Lynne Wilkens
Professor
University of Hawaii at Manoa
Ritin Sharma
Staff Scientist
Translational Genomics Research Institute
Anthony Swerdlow
Professor of Epidemiology
Institute of Cancer Research Sutton
Walter H Gotlieb
McGill University
Matthew Wakefield
University of Melbourne
Martin Widschwendter
Professor; Director
University of Innsbruck
Martin Köbel
Associate Professor
University of Calgary
Estrid V. Hoegdall
University of Copenhagen
Minh Tung Phung
Assistant Professor
University of Wisconsin-Madison
Huihui Fan
Assistant Professor
The University of Texas Health Science Center at Houston John P and Katherine G McGovern Medical School
Paul Timpson
Co-Director ACRF (INCITe) Centre
Garvan Institute of Medical Research
James D Brenton
University of Cambridge
Jae-Weon Kim
Professor
Seoul National University Hospital
Alexander Bishop
Professor
University of Texas Health Science Center at San Antonio
Cezary Cybulski
Pomeranian Medical University
Lyndal Anderson
University of Western Sydney
Claus Høgdall
Professor in Clinical Gynecologic Oncology
University of Copenhagen
Gregg Morin
Associate Professor
The University of British Columbia
Morag Park
McGill University
Hui Shen
Van Andel Institute
Anthony Gill
University of Sydney
Linda Cook
Professor
University of Colorado Cancer Center
Paul James
Head of Adult Genetics
The Royal Melbourne Hospital Royal Park Campus
Parham Minoo
Associate Clinical Professor of Pathology
University of Calgary
Angela Brooks-Wilson
Simon Fraser University
Bernard E. Weissman
University of North Carolina at Chapel Hill School of Medicine
Tomasz Kluz
Professor
Rzeszów University
Joellen Schilkdraut
Professor
Emory University
Michael Anglesio
Associate Professor
The University of British Columbia
Ramona Erber
W2-Professorin, Oberärztin
University of Regensburg
Nicholas Hawkins
Emeritus Professor
UNSW Sydney
Usha Menon
Professor of Gynaecological Oncology
University College London
yvette drew
Associate Professor
The University of British Columbia
Lynda Bennett
Assistant Professor
University of Texas Southwestern Medical Center
Sandra Orsulic
Professor
University of California, Los Angeles
Cheng-Han Lee
Associate Professor
University of Alberta
Ian Campbell
Group Leader
Peter MacCallum Cancer Institute
Stacey J. Winham
Mayo Clinic College of Medicine and Science
Kathleen Cho
University of Michigan
Rafael Meza
Distinguished Scientist
University of Michigan
Elise Graulich
University of Geneva
Jae-Hoon Kim
Yonsei University College of Medicine
Anna H. Wu
Professor
University of Southern California
Marcin Kortylewski
Professor
Beckman Research Institute, City of Hope
Gillian Hanley
Associate Professory
The University of British Columbia
C Blake Gilks
-
Peter Fasching
-
Francesmary Modugno
University of Pittsburgh
Brooke E. Howitt
Stanford University School of Medicine
Alexander Hein
-
Kylie-Ann Mallitt
Senior Lecturer in Biostatistics
University of Sydney
Dale Garsed
University of Melbourne
Philip Crowe
Professor Surgery
University of New South Wales
Renée Fortner
Head of Division
Deutsches Krebsforschungszentrum
K Sundfeldt
Professor/Consultant
University of Gothenburg, Sahlgrenska Academy
Tomasz Huzarski
Pomeranian Medical University
Byoung-Gie Kim
Sungkyunkwan University School of Medicine
Dane Cheasley
Senior Research Fellow
University in Western Australia
Gregg Nelson
Gynecologic Oncologist
University of Calgary
Sidong Huang
McGill University
Jennifer Anne Doherty
Professor
University of Utah
Jessica Lang
Assistant Professor
University of Wisconsin-Madison
Tully Underhill
Professor
The University of British Columbia
Paul Pharoah
Professor of Cancer Epidemiology
Cedars-Sinai Medical Center
Brenda Y Hernandez
University of Hawaii
Michael Edwin Jones
Senior Staff Scientist
Institute of Cancer Research
Kylie L Gorringe
Group Leader
Peter MacCallum Cancer Institute
Jan Lubiński
Head of Dept
Pomeranian Medical University
Mona El-Bahrawy
Imperial College London
Yemin Wang
Assistant Professor
Fred Hutchinson Cancer Research Center
Aleksandra Gentry-Maharaj
University College London
Janusz Menkiszak
Head of the University Clinic
Pomeranian Medical University
Fuchsia Howard
Associate Professor
The University of British Columbia
Clare Scott
Walter and Eliza Hall Institute of Medical Research
Susan Ramus
Professor of Molecular Oncology
University of New South Wales
Paul Cohen
University of Western Australia
Aline Talhouk
Assistant Professor
The University of British Columbia
David Lawson Morris
Professor of Surgery
University of New South Wales
Make your next move.
Prepare your application
Review drafts before you send them.